Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Breast Neoplasms × Carboplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Small Cell Lung Carcinoma 3 Carcinoma 3 Urothelial Cancer 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer 1 Non Small Cell Lung Cancer NSCLC 1 Neurocytoma 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Metastatic Urothelial Cancer 1 Mesothelioma 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Glioma 1 Glioblastoma 1 Ganglioneuroma 1 Ganglioglioma 1 Fallopian Tube Neoplasms 1

Interventions

Trastuzumab 6 Fulvestrant 6 abemaciclib 5 Capecitabine 5 trastuzumab deruxtecan 4 Paclitaxel 4 eribulin 3 Gemcitabine 3 Docetaxel 3 Cyclophosphamide 3 selpercatinib 2 sacituzumab govitecan 2 ribociclib 2 pertuzumab 2 olaparib 2 exemestane 2 Vinorelbine 2 Letrozole 2 Fluorouracil 2 Epirubicin 2 Doxorubicin 2 Anastrozole 2 Ado-Trastuzumab Emtansine 2 130-nm albumin-bound paclitaxel 2 tucatinib 1 talazoparib 1 palbociclib 1 neratinib 1 larotrectinib 1 inavolisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01358877 2025-11-28

APHINITY

Hoffmann-La Roche

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡